<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2952">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068468</url>
  </required_header>
  <id_info>
    <org_study_id>CN002-012</org_study_id>
    <secondary_id>2016-002554-21</secondary_id>
    <nct_id>NCT03068468</nct_id>
  </id_info>
  <brief_title>Study of BMS-986168 in Patients With Progressive Supranuclear Palsy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants With Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of intravenously
      administered BMS-986168 in participants with Progressive Supranuclear Palsy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PSP (Progressive Supranuclear Palsy) Rating Scale</measure>
    <time_frame>Up to 52 Weeks</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>Up to 52 Weeks</time_frame>
    <description>Numbers and Percentages</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>BMS-986168</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986168 intravenous infusion on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intravenous infusion on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986168</intervention_name>
    <description>BMS-986168 intravenous infusion on specified days</description>
    <arm_group_label>BMS-986168</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intravenous infusion on specified days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with probable or possible PSP

          -  Able to ambulate independently or with assistance

          -  Able to tolerate MRI

          -  Have reliable caregiver to accompany participant to all study visits

          -  Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at screening

          -  Participant must reside outside a skilled nursing facility or dementia care facility
             at the time of screening and admission to such a facility must not be planned

        Exclusion Criteria:

          -  Presence of other significant neurological or psychiatric disorders

          -  Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neuron disease

          -  History of early, prominent rapid eye movement (REM) sleep behavior disorder

          -  History of or screening brain MRI scan indicative of significant abnormality

          -  Known history of serum or plasma progranulin level less than one standard deviation
             below the normal patient mean for the laboratory performing the assay

        Other protocol defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>February 27, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
